

1 **SEROPREVALENCE OF HEPATITIS A AND E VIRUS INFECTIONS IN**
2 **PATIENTS WITH ACUTE VIRAL HEPATITIS IN HYDERABAD, INDIA -**
3 **A ONE YEAR STUDY.**

4
5 **Dr. Fatima Sarwat 1*, Dr. Syyeda Anees . Anjum Ayesha 3**

6 *(*sarwatfatima73@gmail.com)*

7 ¹*Professor of Microbiology Princess Esra hospital Deccan College of medical sciences*

8 ²*Professor of Biochemistry Princess Esra hospital Deccan College of medical sciences*

9
10
11
12
13 **ABSTRACT**

INTRODUCTION: Acute viral hepatitis due to faeco- oral group of hepatitis viruses is endemic in India. Outbreaks of Hepatitis E virus infection are more common than the hepatitis A virus.

AIM: The present study aimed at determining the seroprevalence of IgM antibodies to hepatitis A and E virus in clinically diagnosed acute viral hepatitis cases. And to determine its usefulness against the disease prevention.

Study design: A cross sectional study was carried out on symptomatic patients referred from paediatric and gastro enterology department of Princess Esra hospital.

PLACE AND DURATION OF STUDY: Around one hundred and eight subjects were analyzed for anti IgM antibodies to hepatitis A and E virus and liver function test in the department of laboratory medicine for Microbiology and biochemistry at Princess Esra hospital, Deccan College of Medical Sciences between January 2013 and January 2014.

METHODOLOGY: Blood samples were collected under strict aseptic precautions and tested for anti-HAV and Anti-HEV IgM antibodies using capture elisa from diasorin. Biochemical analysis included estimation of serum aminotransferases, alkaline phosphatase and bilirubin levels.

RESULTS: An overall seropositivity of 54% was observed in the present study. More number of the subjects as 46.29% tested positive for anti HAV IgM than for anti HEV IgM as 7.4%. Co-infections were not noticed. Acute viral hepatitis due to hepatitis A virus is more common in children in the age group 6-10 years followed by 11-15 years and lastly 0-5 years indicating the epidemiological shift. Infection with hepatitis E virus was common in adolescent and adults. Males were more susceptible to both the infections than females. Liver function test results correlated well with viral markers indicating damage to the liver parenchyma. The socioeconomic status of the individuals revealed that 95% of the subjects were below poverty line and didn't have access to proper drinking water and sanitary facilities. None were vaccinated against Hepatitis A virus.

Conclusion: The present data suggest that we need to have a dual pronged approach against prevention of acute viral hepatitis caused by A and E virus. Government authorities should prioritize on bringing a uniform improvement in the living standards of the society and make vaccine available to the high risk group at a subsidized rate.

14
15 *Keywords: [Hepatitis A virus, Hepatitis E virus, Acute viral Hepatitis, Anti HAV IgM, Anti HEV*
16 *IgM, Serum aminotransferases, Seroprevalence, HAV Vaccine]*
17

18 **1. INTRODUCTION**

19 Viral hepatitis is an important epidemiological disease caused by any one of the known
20 hepatitis virus and less commonly by some miscellaneous viruses. Among the various
21 hepatitis virus the faecooral group; the Hepatitis A and E virus are highly contagious and
22 spread through consumption of contaminated food and water or by direct contact [1-5].

23 Moreover it is known to be shed in the faeces of both symptomatic and asymptomatic cases
24 and as well during the convalescence phase. It is able to survive in the environment for
25 months which increases the chances of spread in the community [2, 5]. Hepatitis A virus is
26 known to cause asymptomatic infection in 70% of the children below six years [5,6].

27 Whereas in grown up children and adults it leads to symptomatic infection [7-9]. On the
28 contrary Hepatitis E virus is known to cause symptomatic infection in adults and fulminant
29 infection in pregnant women especially in the third trimester with high case fatality rate of
30 20% [10].

31 The sero epidemiological studies on hepatitis A and E are very limited. Off late several
32 studies have demonstrated a gradual decline in the seroprevalence of the disease from 70%
33 - 45% in highly endemic regions and in intermediate region from 45.34 – 3.01 % [11-12]
34 due to socio economical development or urbanization of the society brought about by
35 increased income levels and improved water and sanitation facilities [13-19]. But the
36 findings are not uniform throughout the country therefore epidemiology of the disease
37 caused by hepatitis A is variable and is influenced by heterogeneity observed in the host
38 susceptibility and environmental factors [20].Therefore from time to time outbreaks keep
39 occurring in the developing countries [21-24] .

40 The role of vaccine in prevention of diseases is biased or debatable as most of the authors
41 are of the opinion that vaccine is not essential. The present data shows that majority of the
42 children between 5-10 years of age show presence of anti HAV antibodies in the range of 90
43 - 96.9% respectively. Hence vaccine is not permissible in highly endemic regions [17, 25 –
44 37].

45 Aim –To determine the seroprevalence of Hepatitis A and E virus infections in acute viral
46 hepatitis cases attending princess Esra hospital a tertiary care hospital in Hyderabad during
47 a one year period from Jan. 2013- Jan. 2014. To determine the significance of this data in
48 HAV vaccination planning and other protective measures for prevention of HAV infection.

49 **2. MATERIAL AND METHODS**

50

51 **Case definition as per [WHO] WORLD HEALTH ORGANIZATION**

52 An acute viral hepatitis case was defined as a person having an acute illness of <
53 15 days duration with a discrete onset of any sign or symptom of fever,

54 headache, malaise, anorexia, nausea, vomiting, diarrhoea and abdominal pain
55 with jaundice or elevated levels of aminotransferases levels > 100 IU/L
56 documented at least twice at a one week interval without any history of pre existing
57 liver disease [38].

58 **EXCLUSION CRITERIA**

59 Patients with symptoms of alcoholic liver disease, Chronic liver disease and those
60 with the history of HAV vaccination were excluded from the study.

61 A prospective cross sectional study on one hundred and eight patients fulfilling the
62 above case definition criteria of acute viral hepatitis referred from paediatric and
63 gastroenterology department of Princess Esra hospital during the period from
64 January 2013 to January 2014 were included in the study.

65 After obtaining an informed oral consent from each patient about 5ml blood was
66 collected in BD vacutainers under aseptic precautions. Blood was allowed to clot
67 and serum used for liver function test and hepatitis markers like Anti HAV IgM and
68 Anti HEV IgM from Diasorin Italy. Assay based on IgM capture ELISA.

69 Quality control – was achieved by running the internal and external quality control
70 samples during the run and repeating the positive test samples twice.


71 **DATA ANALYSIS** – The study data was analyzed using the EPI INFO 7 software
72 from [CDC] Centers for Disease Control and Prevention.

73 **3. RESULTS**

74

75 Of the one hundred and eight individuals with sign and symptoms of acute viral
76 hepatitis 54% gave a positive serological result for Hepatitis A and E Anti IgM.

77 Hepatitis A alone accounted for 46.29 % and hepatitis E for 7.40% respectively.



78

79 **THE DEMOGRAPHIC PROFILE**

80 Table 1 shows the demographic data of the subjects in study with specific reference
 81 to seropositive individuals. More number of males were symptomatic for the disease
 82 than females. The overall mean age for the Anti HAV IgM positive individuals is
 83 significantly less when compared to anti HEV IgM positive individuals with a *P* value
 84 of 0.001 . Further, it is seen that there is an age specific variation in the exposure
 85 rates to hepatitis A and E virus .Hepatitis A infection is more prevalent in young
 86 children than in grownups and adults which is common with hepatitis E infection with
 87 a significant *P value* of less than 0.05. Majority of the subject's positive for acute
 88 viral hepatitis were males 64% than females as 36%.

89 **TABLE 1- DEMOGRAPHIC PROFILE OF SUBJECTS IN STUDY.**

90


Factor	Number	Percentage
SEX		
Male	74	68.5
Female	34	31.5
AGE		
Mean age for anti HAV Positive subjects	10.84±6.08	
Males	9.60 ± 4.68	
Females	12. 70 ± 7.489	
Mean age for Anti HEV IgM Positive subjects	26.25 ± 9.40	
Males	26.57 ± 10.11	
Females	24.00 ±0.00	
SEROPOSITIVE SUBJECTS		
Anti HAV IgM Positive	50	46

Males	30	34
Females	20	18.5
Anti HEV IgM Positive	8	7.4
Males	7	6.48
Females	1	0.92
AGE OF MAXIMUM EXPOSURE TO HAV INFECTION		
0-5	8	16
6-10	22	44
11-15	12	24
16-20	3	6
21-25	5	10
AGE OF MAXIMUM EXPOSURE TO HEV INFECTION		
16-20	3	37.5
21-25	2	25
26-30	1	12.5
36-40	2	25
SOCIOECONOMIC STATUS OF ANTI HAV IgM POSITIVE SUBJECTS		
Group	Number	Percentage
Low socioeconomic group	48	95
Lower middle socioeconomic group	2	5
SOCIOECONOMIC STATUS FOR ANTI HEV IgM POSITIVE SUBJECTS		
Lower middle socioeconomic group	6	75
Upper middle socioeconomic group	2	25
Facilities available	Yes %	No %

Access to potable water	5	95
Toilet facility	5	95
Education	4	96
Occupation petty jobs	96	4
Slum dwellers [migrants]	95	5

91

92 With respect to gender both Hepatitis A and E infection are seen to be common in
 93 males accounting for 60% and 87.5% of the infections respectively. Therefore based
 94 on gender and age the above findings show that HAV infection is more common in
 95 the age group 6-10years whereas HEV infection is common in the age group 16-20
 96 followed by 21-25 years. Further in the study it is observed that in females aged 21-
 97 25 years the prevalence of acute HAV infection is comparatively higher than HEV
 98 infection due to reasons unknown. Graph -2



99

100 **INFLUENCE OF ENVIRONMENTAL FACTORS ON DISEASE PREVALENCE -**

101 While taking history from seropositive patients we have noticed that for Hepatitis A
 102 infection 95% of the people belonged to below poverty line and didn't have any
 103 access to potable water. They were migrants and slum dwellers with no proper
 104 sanitation facilities and knowledge about personal hygiene. On the other side
 105 hepatitis E infection were seen in low and upper middle socioeconomic group of the
 106 society. None were vaccinated against HAV.

107 The results of liver function test showed a significant correlation with the viral
108 markers for HAV and HEV. Except for two cases of acute viral hepatitis 96% of them
109 had raised aminotranferases, alkaline phosphatase and bilirubin levels in their
110 serum. The mean serum levels for these parameters were as follows for alanine
111 aminotransferase 708.5 ± 650.774 IU/L, for aspartate aminotransferase as $375.5 \pm$
112 571.818 IU/L and for alkaline phosphatase as 344.00 ± 149.563 IU/L. The mean
113 serum total bilirubin level was about 5.0 ± 3.00 . Hence it is evident that all patients
114 were facing severe hepatocellular injury due to viral infection.

115 **DISCUSSION**

116 Hepatitis A and E viral infection are endemic in many developing countries [39].
117 India is the homeland with high endemicity rates for both the infections [16,37,
118 40,41]. The seroprevalence rates for hepatitis A IgG antibodies are almost 100%
119 in adult population [27,36,40]. The virus continues to lurk in some pockets of the
120 society due to various environmental and host factors and causes sporadic and
121 epidemics from time to time [41]. There are hardly few studies providing data on
122 acute viral hepatitis caused by hepatitis A and E virus from India [32,42-44]. Most of
123 the studies done so far in India have either determined the serum anti HAV IgG or
124 total antibodies i.e. anti HAV IgM and IgG together which indicate convalescence
125 following infection or immunity against infection due to infection or immunization
126 and are useful in epidemiological studies and developing vaccination strategies [
127 25,32,45-46]. Our study aimed at determining the anti HAV IgM response which
128 signifies acute infection rates in the society after the so called epidemiological shift
129 or transition that has been documented by many authors [20 30, 40, 47-48]
130 We observed an overall seroprevalence rate of 54% which is less when compared to
131 the one reported as 96.9% by B Mohanvalli et al and 81.88% by Deepak arora et al
132 2013 from Punjab. Out of this hepatitis A alone accounted for 46.29 % of the cases
133 and E for 7.40 % which is almost reverse of what has been documented by Deepak
134 arora as 13.9% for hepatitis A and 78.78% for hepatitis E and Singh et al as 32.1%,
135 [42, 50] . In some studies very low prevalence rates for hepatitis A has been
136 recorded like the one reported by by Mehta et al 2013 as 19.15% and 6.87% by SR

137 et al 2012 [43-44] . Further some authors have reported co-infections too in their
138 studies resulting from simultaneous infection by both hepatitis A and E virus like
139 the one by Deepak et al as 7.5%, 8.6% by B Mohan valli and 8.9% by SR et al
140 which is not seen in our case [32,42, 44] . The differences in the seroprevalence
141 rates for the two viruses observed in various geographical region of the same country
142 from North West to south India could be because of the heterogenicity in the host
143 and environmental factors influencing it [51]. In the present study we noticed that
144 disease is more common in males 65.5% which is consistent with the report by SR
145 et al of 67.5% and others [42-44] one of the reasons for this male predominance
146 could be the early outside association of the male gender as mentioned by other
147 authors [44 ,52-54]. Males get exposed to the environment earlier than females in
148 some orthodox societies and cultures.

149 On the basis of age we noticed that for reasons unknown hepatitis A infection is
150 more common in childhood whereas hepatitis E is more common in adults which
151 corroborates with findings of Aggarwal R et al [51].As per the data on the
152 seroepidemiology of hepatitis A it is known that 96.9 % of the children by the age of
153 15 years acquire protective antibodies indicating exposure to the virus at an early age
154 of less than 5 years [32].In our study we have seen that maximum exposure to
155 infection occurred in the age group order of 6-10 years followed 11-15 years and
156 then 0-5 years which signifies an epidemiological transition [20, 32 ,55]. On the
157 contrary most of the hepatitis E virus infections occurred in the age group 16-20
158 years followed by 21-25 and then 36-40 years. Age specific variations in the
159 epidemiology of the two viruses in a same place are not very much explained [16].
160 Poverty and inadequate personal hygiene are strongly associated with the infection
161 rates [42]. It is said that seroprevalence rates of hepatitis A and E are inversely
162 proportional to the economic status of the individuals, supply of protected water
163 supply and personal and environmental hygiene. There are several reports
164 demonstrating the association between living standards and prevalence of hepatitis A
165 and E. between the high and low income groups and the rural and urban population.
166 It is noticed that 80-90 % of the seropositivity is seen in low socioeconomic and rural

167 population than in urban and high income group same has been observed in our
168 study too [19,32,40,56,57]. Ninety five percent of the exposed people in case of
169 hepatitis A infection belonged to below poverty line and were migrants from
170 neighboring states or countries with nil personal and environmental hygiene
171 measures [17, 20, 30, 36, 37, 46, 48, 56- 58] But in case of hepatitis E infection
172 positive individuals were from both from low and middle economic class and had
173 access to protected water supply or sanitation.

174 Therefore the thought to include vaccination against HAV in the universal
175 immunization programme needs to be contemplated before being implemented as
176 lack of appropriate epidemiological data from the various corners of the country and
177 of course the cost of the vaccine are the major obstacles noticed. Disease prevention
178 by provision of protected water supply and improved sanitary conditions still
179 remains a dream in many areas of the Indian subcontinent. Therefore at this stage of
180 economical development it is difficult to comment on inclusion of HAV vaccine in
181 the national immunization program and it is the decision of the policy makers. But of
182 course disease prevention by improving living standards holds relevance.

183 In acute viral hepatitis the biochemical markers are 96% sensitive for the viral
184 etiology of the disease. Therefore it is always good to monitor the patients along with
185 the viral markers the serum aminotrasferases and bilirubin levels.

186 **4. CONCLUSION**

187
188 Therefore it appears cognizant to have a target approach with vaccination of the high
189 risk group at a subsidized rate by the ministry of health and family welfare and focus
190 on economical and environmental development which will definitely reduce the
191 seroprevalence of acute viral hepatitis by faeco-oral group of virus as it is quoted that
192 these infections are an index of socio economical status of a country [36].

193

194 **ACKNOWLEDGMENT**

195

196 The authors are thankful to the institution for granting permission to carry out the

197

198 study and the technical staff of the central laboratories in providing timely help.

199

200 **COMPETING INTERESTS**

201

202 None

203

204 **AUTHORS' CONTRIBUTIONS**

205

206 'Author Dr. Sarwat Fatima' designed the study, performed the statistical analysis, wrote the

207 protocol, and wrote the first draft of the manuscript did review of the literature. 'Author B'

208 managed the biochemical analyses of the study. 'Author C' managed the analyses of viral

209 markers. All authors read and approved the final manuscript."

210

211

212 **CONSENT**

213

214 An informed oral consent was obtained from all the study subjects prior to testing.

215

216 **ETHICAL APPROVAL**

217

218 Ethical approval was obtained from institutional ethics committee.

219

220 **LIMITATIONS**

221 We regret our inability to obtain complete demographic data from all the study

222 subjects which is essential for establishing the role of various environmental factors

223 in disease etiology due to lack of technical support. Any how we tried our level best

224 to get proper information from at least the seropositive group.

225

226 **REFERENCES**

227

228 1. Hollinger FB, Ticehurst JR. Hepatitis A virus. In: Fields BN, Knipe DM, Howley

229 PM, editors. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven; 1996. p.

735-82.

230

231 2. Stapleton JT, Lemon SM. Hepatitis A and hepatitis E. In: Hoeprich PD, Jordan

232 MC, Ronald AR, editors. Infectious Diseases. 5th ed. Philadelphia: Lippincott

233 Co.; 1994. p. 790-7.

234

235 3. Lemon SM. Type A viral hepatitis: Epidemiology, diagnosis, and prevention.

236 Clin Chem 1997;43:1494-9.

- 235 4. Lemon SM. Hepatitis A virus. In: Webster RG, Granoff A, editors. Encyclopedia
236 of Virology. London: Academic Press Ltd.; 1994. p. 546-54.
- 237 5. Gust ID. Epidemiological patterns of hepatitis A in different parts of the world.
238 *Vaccine* 1992;10 Suppl 1:S56-8.
- 239 6. Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-
240 care centers. A community-wide assessment. *N Engl J Med* 1980;302:1222-7.
- 241 7. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW.
242 Frequency of illness associated with epidemic hepatitis A virus infection in
243 adults. *Am J Epidemiol* 1985;122:226-33.
- 244 8. Kamar N, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, Cointault O,
245 Esposito L, Abravanel F, Danjoux M, Hepatitis E virus and chronic hepatitis in
246 organ-transplant recipients *N Engl J Med* 2008 358:811-17.
- 247 9. Kunasol P, Cooksley G, Chan VF, Isahak I, John J, Loleka S, et al. Hepatitis A
248 virus declining seroprevalence in children and adolescents in Southeast Asia.
249 *Southeast Asian J Trop Med Public Health* 1998; 29(2):255-262.
- 250 10. Arankalle VA. Hepatitis A vaccine strategies and their relevance in the present
251 scenario. *Indian J Med Res* 2004; 119 (5): iii-vi
- 252
- 253 11. Amela C, Pachon I, Bueno R, Miguel de C, Navarro MF. Trends in hepatitis A
254 virus infection with reference to the process of urbanization in the greater Madrid
255 area (Spain). *Eur J Epidemiol* 1995; 11 : 569-73.
- 256
- 257 12. Kremastinou J, Kalapothaki V, Trichopoulos D. The changing epidemiologic
258 pattern of hepatitis A infection in urban Greece. *Am J Epidemiol* 1984; 120 : 703-
259 6.
- 260 13. Schwartz Eli, Raveh D. The prevalence of hepatitis A antibodies among Israeli
261 Travelers and the economic feasibility of screening before vaccination. *Int J*
262 *Epidemiol* 1998; 27 : 118-20.

263

- 264 14. Shaw FE, Halder SC Jr, Maynard JE. Hepatitis A in Mauritius: an apparent
265 transition from endemic to epidemic transmission patterns. *Ann Trop Med*
266 *Parasitol* 1989; 83 : 179-85.
267
- 268 15. Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis
269 A virus infection. *J Hepatol* 1993; 18 (Suppl 2): S11-4.
270
- 271 16. Arankalle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee K, *et*
272 *al.* Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune,
273 India, 1982 and 1992. *J Infect Dis* 1995;171:447-50.
274
- 275 17. Mall ML, Rai RR, Philip M, Naik G, Parekh P, Bhawnani SC, *et al.*
276 Seroepidemiology of hepatitis A infection in India: Changing pattern. *Indian J*
277 *Gastroenterol*2001;20:132-5.
278
- 279 18. Das K, Jain A, Gupta S, Kapoor S, Gupta RK, Chakravorty A, *et al.* The
280 changing epidemiological pattern of hepatitis A in an urban population of India:
281 Emergence of a trend similar to the European countries. *Eur J Epidemiol*
282 2000;16:507-10.
- 283 19. Dhawan PS, Shah SS, Alvares JF, Kher A, Shankaran K, Kandoth PW, *et al.*
284 Seroprevalence of hepatitis A virus in Mumbai, and immunogenicity and safety
285 of hepatitis A vaccine. *Indian J Gastroenterol* 1998;17:16-8.
- 286 20. Mathur P, Arora NK. Epidemiological transition of hepatitis A in India: Issues
287 for vaccination in developing countries. *Ind. J. Med. Res.* 128 Dec 2008:699-704.
- 288 21. Arankalle VA, Sarada Devi KL, Lole KS, Shenoy KT, Verma V, Haneephabi M.
289 Molecular characterization of hepatitis A virus from a large outbreak from
290 Kerala, India. *Indian J Med Res* 2006;123:760-9.
- 291 22. Chobe LP, Arankalle VA. Investigation of a hepatitis A outbreak from Shimla
292 Himachal Pradesh. *Indian J Med Res* 2009;130:179-84.

- 293 23. Sowmyanarayanan TV, Mukhopadhyaya A, Gladstone BP, Sarkar R, Kang G.
294 Investigation of a hepatitis A outbreak in children in an urban slum in Vellore,
295 Tamil Nadu, using geographic information systems. *Indian J Med Res*
296 2008;128:32-7.
- 297 24. Chadha MS, Lole KS, Bora MH, Arankalle VA. Outbreaks of hepatitis A among
298 children in western India. *Trans R Soc Trop Med Hyg* 2009;103:911-6.
- 299 25. Salahuddin M, Bazlul Karim A.S.M. 2Jahangir Alam , Md. 3.Age-specific
300 prevalence of antibodies to Hepatitis A virus among Bangladeshi children .*DS*
301 (Child) *H J* 2012; 28 (1) : 31-34
- 302 26. Kamath SR, Sathiyasekaran M, Raja TE, Sudha M. Profile of viral hepatitis A in
303 Chennai. *Indian Pediatrics* 2009; **46**: 642-43.
- 304 27. Agboatwalla M, Isomura S, Miyake K, Yamashita T, Morishita T, Akram DS.
305 Hepatitis A, B and C seroprevalence in Pakistan. *The Indian Journal of Pediatrics*
306 1994; **61**: 545-49.
- 307 28. WHO. Department of communicable disease surveillance and response, *Hepatitis*
308 *A* 2000; 1-39.
- 309 29. Saha SK, Setarunnahar S, Shakur S, Hanif M, Habib MA, Dutta SK, et al.
310 Seroprevalence of hepatitis A infection by age group and socioeconomic status of
311 Bangladesh. *13th International Congress on Infectious Diseases Abstracts,*
312 *Poster Presentations* 2008; **16**(43):101-02.
- 313 30. Raharimanga V, Carod JF, Ramarokoto CE, Chertien JB, Rakotomanana F,
314 Talarmin A, et al. Age specific seroprevalence of hepatitis A in Antananarivo
315 (Madagascar). *BMC Infectious Diseases* 2008; **8**(78): 1-6.
- 316 31. Sheikh A, Sugitani M, Kinukawa N, Moriyama M, Arakawa Y, Komiyama K, et
317 al. Hepatitis E virus infection in fulminant hepatitis pattern and an apparently
318 healthy population in Bangladesh. *American Journal of Tropical Medicine and*
319 *Hygiene* 2002; **66**(6): 721-24.
- 320 32. Mohanavalli B, Dhevahi E, Menon T, Malathi S, Thyagarajan SP . Prevalence of
321 antibodies to hepatitis A and hepatitis E virus in urban school children in
322 Chennai. *Indian Pediatr* 2003; 40 : 328-31.

- 323 33. Thapa BR, Singh K, Singh V, Broor S, Singh V, Nain CK. Pattern of hepatitis A
324 and hepatitis B virus markers in cases of acute sporadic hepatitis and in healthy
325 school children from North West India. *J Trop Pediatr* 1995; 41: 328-329.
- 326 34. Aggarwal R, Naik S, Yachha SK, Naik SR. Seroprevalence of antibodies to
327 hepatitis A virus among children in Northern India. *Indian Pediatr* 1999; 36:
328 1248-1250
- 329 35. Tsarev SA, Emerson SU, Reyes GR, Tsarevq TS, Kapikian AZ, Ticehurst J *et al.*
330 Characterization of a prototype strain of hepatitis E virus. *Proc Natl Acad Sci*
331 USA, 1992; 89: 559-563.
- 332 36. Ahmed M, Munshi SU, Nessa A. High prevalence of hepatitis A virus antibody
333 among Bangladeshi children and young adults warrants pre-immunization
334 screening of antibody in HAV vaccination strategy. *IJMM* 2009; vol 27 issue 1
- 335 37. Batra Y, Bhatkal B, Ojha B, Kaur K, Saraya A, Panda SK, *et al.* Vaccination
336 against hepatitis A virus may not be required for school children in northern India:
337 results of a seroepidemiological survey. *Bull World Health Organ* 2002; 80 : 728-
338 31.
- 339
- 340 38. United States Centers for Disease Control and Prevention. 2012 National
341 Notifiable Diseases and Conditions and Current case Definitions. Available
342 from: http://www.cdc.gov/nndss/document/2012_Case%20Definitions.pdf. [Last
343 accessed on 2012 May 16].
- 344 39. Kar P. Is there a change in seroepidemiology of hepatitis A infection in India?
345 *Indian J Med Res* 2006; 123(6):727-729.
- 346 40. Tandon BN, Gandhi BM, Joshi YK. Etiological spectrum of viral hepatitis and
347 prevalence of markers of Hepatitis-A and B virus infection in North India. *Bull*
348 *World Health Organ* 1984; 62 (1) : 67-73.
- 349 41. Dittman S. International congress on viral hepatitis A and B: Experience in
350 education and prevention. *Vaccine* 2000; 18:S1-2.
- 351 42. Rakesh p, Sherin D, Sankar Hari. Investigating a community – wide outbreak of
352 hepatitis A in india. *Journal of global infectious disease* 2014; vol 6 issue 2.

- 353 43. Arora D, Jindal N, Shukla RK. Water borne hepatitis A and E in malwa region
354 Punjab India. *J Clin Diag Res*. 2013; vol7 issue 10-2163-66.
- 355 44. Mehta K, Shruti S, Shingala H. Prevalence of Hepatitis A in clinically suspected
356 cases of acute viral hepatitis in Jamnagar, Gujarat, India. *IJSR*. 2013; Vol2 issue 4
357 13-14.
- 358 45. Syed R, Mohammed A, Sindiri P et al. Seroepidemiology of hepatitis A virus in
359 Hyderabad, South India. *J Med A lli e d S c i 2 0 1 2 ; 2 (2) : 58-61*.
- 360 46. Verma YS, Rajput SS, Rajput N. Seroprevalence of hepatitis A infection in
361 children. *SJAMS*. 2014; 2(3D):1144-47.
- 362 47. Chadha MS, Chitambar SD, Arankalle VA. Exposure of Indian children to hepatitis A
363 virus and vaccination age. *IJ Med. Res.* 1999; Jan; 109:11-15.
364
- 365 48. Mittal SK, Rastogi A, Kumar N, Talukdar B, Kar P. Seroprevalence of hepatitis
366 A in children - Implications for hepatitis A vaccine. *Trop Gastroenterol* 1998; 19
367 : 120-1.
368
- 369 49. Joshi N, Nagarjuna KYR, Kumar A. Age related seroprevalence of antibodies to
370 hepatitis A virus in Hyderabad, India. *Trop Gastroenterol* 2000; 21 : 63-5.
371
- 372 50. Singh J, Prakash C, Gupta RS, Bora D, Jain DC, Datta KK. Epidemiology of
373 endemic viral hepatitis in an urban area of India: a retrospective community
374 study in Alwar. *Bull World Health Organ* 1997; 75 : 463-8.
375
- 376 51. Aggarwal R, Krawczynski K. Hepatitis E: An overview and recent advances in
377 clinical and laboratory research. *J Gastroenterol Hepatol*. 2000; 15 (1) :9-20.
378
- 379
- 380 52. Amarapurkar DS, Agar Baijal P, Gupte P, Kamani N. Epidemiology of Hepatitis
381 E Virus Infection in Western India. *Journal of Hepatic Monthly*. 2008; 8 (4):258-
382 62.

- 383 53. Aggarwal R, Shahi H, Naik S, Yachha SK, Naik SR. Evidence in favour of high
384 infection rate with hepatitis E virus among young children in India. *J Hepatol.*
385 1997; 6(6):1425-6.
- 386 54. Rao P, Shenoy SM, Baliga S, Joon A. Prevalence of HAV and HEV in the
387 patients presenting with acute viral hepatitis. *BMC Infectious Diseases.* 2012;
388 12(Suppl 1):1471-2334-12-S1-P30.
- 389 55. Dutta AK, Aggarwal A, Kapoor AK, Ray GN, Batra S. Seroepidemiology of
390 hepatitis A in children in Delhi. *Indian. J Pediatr.* 2000; 67 : 77-9.
- 391
- 392 56. Zago MP, Stantolin GC, Perazzio S. Prevalence of antihepatitis A antibodies in
393 children of different socioeconomic conditions in Vila Velha. *Rev Soc bras Med*
394 *trop.* 2005; 38:285-89.
- 395 57. Pereira FE, Gonçalves SC. Hepatite A. *Rev Soc bras Med trop.* 2003; 36:387-
396 400.
- 397 58. Das K, Kar P, Chakraborty A, Gupta S, Das BC. Is vaccination program against
398 hepatitis A needed in India? *Indian J Gastroenterol* 1998; 17 : 158.

399

400 **ABBREVIATIONS**

401 **HAV – HEPATITIS A VIRUS**

402 **HEV – HEPTITIS E VIRUS**

403 **WHO – WORLD HEALTH ORGANIZATION**

404 **ANTI HAV IGM – HEPATITIS A IGM ANTIBODIES**

405 **ANTI HEV IGM – HEPATITIS E IGM ANTIBODIES**

406 **CDC – CENTRE FOR DISEASE CONTROL AND PREVENTION**

407	APPENDIX
408	TITLE
409	AUTHORS DETAILS
410	ABSTRACT
411	KEYWORDS
412	MANUSCRIPT
413	INTRODUCTION
414	MATERIAL AND METHODS
415	RESULTS
416	DISCUSSION
417	CONCLUSION
418	COMPETING INTEREST
419	AUTHORS CONTRIBUTIONS
420	REFERENCES
421	ABBREVIATIONS